home / stock / rare / rare news

RARE News and Press, Ultragenyx Pharmaceutical Inc. From 02/15/24

Stock Information
Company Name: Ultragenyx Pharmaceutical Inc.
Stock Symbol: RARE
Market: NASDAQ
Website: ultragenyx.com
Menu
RARE RARE Quote RARE Short RARE News RARE Articles RARE Message Board
Get RARE Alerts

News, Short Squeeze, Breakout and More Instantly...
RARE - Ultragenyx Pharmaceutical GAAP EPS of -$1.52 beats by $0.10, revenue of $127.39M beats by $5.34M

2024-02-15 16:02:14 ET More on Ultragenyx Pharmaceutical A Deeper Look At Ultragenyx Pharmaceutical DOJ says Ultragenyx to pay $6M to resolve Medicare claims allegations Wells Fargo starts Ultragenyx coverage with overweight rating Seeking Alpha’s Quan...
RARE - Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

2023 Total Revenue of $434 million, Crysvita® revenue of $328 million and Dojolvi® revenue of $71 million 2024 Financial Guidance: Total Revenue between $500 million and $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 million to $80 m...

RARE - Outperform Recommendation Issued On RARE By Wells Fargo

2024-02-15 11:30:02 ET Wells Fargo analyst issues OUTPERFORM recommendation for RARE on February 15, 2024 11:00AM ET. The previous analyst recommendation was Outperform. RARE was trading at $46.41 at issue of the analyst recommendation. The overall analyst consensus : BU...

RARE - Ultragenyx Pharmaceutical Q4 2023 Earnings Preview

2024-02-14 14:07:02 ET More on Ultragenyx Pharmaceutical A Deeper Look At Ultragenyx Pharmaceutical DOJ says Ultragenyx to pay $6M to resolve Medicare claims allegations Wells Fargo starts Ultragenyx coverage with overweight rating Seeking Alpha’s Quan...
RARE - Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update

NOVATO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...

RARE - Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)

NOVATO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF) in patients with...

RARE - Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome

GTX-102 is the first Angelman syndrome therapeutic candidate to receive PRIME designation Phase 1/2 study fully enrolled; expansion data expected in first half of 2024 NOVATO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced t...
RARE - Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

Safety and initial efficacy data from Stage 1 expected in the first half of 2024 Dose selection and initiation of Stage 2 to follow in the second half of 2024 NOVATO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all p...

RARE - Overweight Recommendation Issued On RARE By Wells Fargo

2024-01-19 09:45:01 ET Wells Fargo analyst issues OVERWEIGHT recommendation for RARE on January 19, 2024 10:00AM ET. The previous analyst recommendation was Overweight. RARE was trading at $43.77 at issue of the analyst recommendation. The overall analyst consensus : BUY...

RARE - Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta (OI) conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q 2024 and 1H 2024, respectively; Additional Phase 2 data expected in 2024 Alignment on de...
Previous 10 Next 10